21.03.2014
- Novo Nordisk should still be able to introduce its long-acting insulin Tresiba on the U.S. market before rival products, despite being hit by a delay, the CEO of the Danish...
07.06.2013
- In a leafy suburb of Frankfurt, a state-of-the-art plant churns out up to 1 million insulin pens every day in French drugmaker Sanofi's drive to keep its no. 2 spot in the $43...
02.05.2013
- Sanofi is stepping up the development of a fixed combination of diabetes treatments Lantus and Lyxumia to sidestep an earlier setback with a similar pen device and take advantage...
01.05.2013
- Denmark's Novo Nordisk could see the U.S. launch of its biggest drug hope, a new long-acting insulin, delayed until 2018 while it conducts more tests to satisfy regulators, it said...
31.01.2013
- The world's biggest insulin producer Novo Nordisk raised sales and profit forecasts for 2013 on hopes its new Tresiba drug will soon win approval in the United States and add...
09.08.2012
- Denmark's Novo Nordisk hiked its full-year sales and profit targets after rising demand for diabetes drug Victoza and insulins helped the company beat second-quarter expectations...
08.06.2012
- Danish drugmaker Novo Nordisk , the world's biggest insulin maker, said on Friday that U.S. health regulators had extended their review of its new ultra-long-acting insulin Tresiba...
01.06.2012
- Sanofi aims to build on its diabetes portfolio, which has so far relied on blockbuster insulin Lantus, with a wider range of treatments that could address not just the disease but...
